Literature DB >> 25425443

Continuous administration of linezolid in pneumonia: what is the level of proof?

Olivier Mimoz1, Philippe Montravers, José-Artur Paiva.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25425443     DOI： 10.1007/s00134-014-3572-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  16 in total

1.  Predictors of pulmonary complications after bariatric surgery.

Authors:  Prateek K Gupta; Himani Gupta; Manu Kaushik; Xiang Fang; Weldon J Miller; Lee E Morrow; R Armour-Forse
Journal:  Surg Obes Relat Dis       Date:  2011-05-13       Impact factor: 4.734

2.  Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.

Authors:  Gennaro De Pascale; Serena Fortuna; Mario Tumbarello; Salvatore Lucio Cutuli; MariaSole Vallecoccia; Teresa Spanu; Giuseppe Bello; Luca Montini; Mariano Alberto Pennisi; Pierluigi Navarra; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2014-11-21       Impact factor: 17.440

Review 3.  Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.

Authors:  Matthew S Dryden
Journal:  J Antimicrob Chemother       Date:  2011-05       Impact factor: 5.790

4.  Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.

Authors:  Margreke J E Brill; Aletta P I Houwink; Stephan Schmidt; Eric P A Van Dongen; Eric J Hazebroek; Bert van Ramshorst; Vera H Deneer; Johan W Mouton; Catherijne A J Knibbe
Journal:  J Antimicrob Chemother       Date:  2013-11-08       Impact factor: 5.790

5.  Pharmacokinetics of linezolid in septic patients with and without extended dialysis.

Authors:  Stefanie Swoboda; Michael C Ober; Christoph Lichtenstern; Soundos Saleh; Vedat Schwenger; Hans-Günther Sonntag; Walter Emil Haefeli; Georg Hempel; Torsten Hoppe-Tichy; Markus A Weigand
Journal:  Eur J Clin Pharmacol       Date:  2009-12-16       Impact factor: 2.953

6.  Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock.

Authors:  Céline Pangault; Yves Le Tulzo; Pierre Tattevin; Valérie Guilloux; Nadège Bescher; Bernard Drénou
Journal:  Crit Care Med       Date:  2006-04       Impact factor: 7.598

7.  Risk factors for a low linezolid trough plasma concentration in acute infections.

Authors:  Laura Morata; Marta Cuesta; Jhon F Rojas; Sebastian Rodriguez; Merce Brunet; Gregori Casals; Nazareth Cobos; Cristina Hernandez; José A Martínez; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

8.  Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections.

Authors:  Dario Cattaneo; Giovanna Orlando; Valeria Cozzi; Laura Cordier; Sara Baldelli; Stefania Merli; Serena Fucile; Cecilia Gulisano; Giuliano Rizzardini; Emilio Clementi
Journal:  Int J Antimicrob Agents       Date:  2013-04-04       Impact factor: 5.283

9.  Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.

Authors:  Chiara Adembri; Stefania Fallani; Maria Iris Cassetta; Silvia Arrigucci; Alessandra Ottaviano; Patrizia Pecile; Teresita Mazzei; Raffaele De Gaudio; Andrea Novelli
Journal:  Int J Antimicrob Agents       Date:  2007-12-04       Impact factor: 5.283

10.  Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study.

Authors:  Michael Zoller; Barbara Maier; Cyrill Hornuss; Christina Neugebauer; Gundula Döbbeler; Dorothea Nagel; Lesca Miriam Holdt; Mathias Bruegel; Thomas Weig; Béatrice Grabein; Lorenz Frey; Daniel Teupser; Michael Vogeser; Johannes Zander
Journal:  Crit Care       Date:  2014-07-10       Impact factor: 9.097
View more
  2 in total

Review 1.  Are Antibiotics Appropriately Dosed in Critically Ill Patients with Augmented Renal Clearance? A Narrative Review.

Authors:  Mohammad Sistanizad; Rezvan Hassanpour; Elham Pourheidar
Journal:  Int J Clin Pract       Date:  2022-01-31       Impact factor: 3.149

2.  Continuous Versus Intermittent Linezolid Infusion for Critically Ill Patients with Hospital-Acquired and Ventilator-Associated Pneumonia: Efficacy and Safety Challenges.

Authors:  Ahmed E Abou Warda; Rania M Sarhan; Hussein Saeed Al-Fishawy; Ayman N Moharram; Heba F Salem
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.